Dr Kiran Mazumdar, CMD, Biocon
Mexico has been a very important market for Biocon since 2006, where it has been playing a significant role in enabling access to affordable rh-Insulin.
Insulin Glargine will augment the affordable insulin therapy for diabetes management.
‘GALACTUS' by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012.
Biocon's presence in Mexico, over the last eight years, has expanded the insulins market substantially by initiating many more patients onto insulin therapy.
The increasing affordability of Insulin Glargine will now enable Biocon and PiSA to expand this reach further.
The combined market for Insulin Glargine in Mexico is estimated to be in excess of USD 40 million.